LoFric® Origo™ is designed to provide safe, hygienic and convenient catheterization. Is is foldable to pocket size, discreet, and easy-to-use. The adjustable insertion grip allows non-touch technique offering the user a safe catheterization experience, while ensuring comfort, control, and discretion in a clever packaging.
LoFric catheters are the only hydrophilic catheters available with Urotonic™ Surface Technology. Once activated, Urotonic™ Surface Technology creates minimal friction during the entire process of catheterization due to a hydrophilic surface which is isotonic to urine. Therefore, LoFric catheters slide in and out of the urethra smoothly and with minimal friction – making catheterization more comfortable and safe over time.
A ready to use catheter developed for men, LoFric Origo enables user-friendly intermittent catheterization. It is discreetly packaged and foldable to pocket size, making LoFric Origo easy to carry and use wherever you are. LoFric Origo is designed with an adjustable Insertion Grip which offers better hygiene and control. Based on the unique Urotonic Surface Technology, LoFric Origo also ensures safe and smooth catherization and minimizes health complications, even in the long term.
• Package doubles as a disposable pouch.
Fits in a pocket:
• Foldable to pocket size and easy to bring along.
Instant activation – always fresh:
• All it takes is a gentle squeeze to activate the catheter for use.
Easy to open:
• The convenient peel-open label makes it easy to open and access the activated catheter.
Adhesive tab for convenient hanging:
• For reliable attachment to any dry and clean surface
Hygienic and easy to handle:
• The adjustable Insertion Grip gives control without having to touch the catheter tube during insertion. This means lower the risk of contaminating the catheter, which minimizes the risk of infection.
LoFric Catheters are scientifically proven to show:
• 0% trauma after 5-9 years with LoFric. 1
• 10-20 times lower expected risk of strictures. 2
• 64% lower expected risk of UTIs. 3
• 48% lower expected risk of hematuria. 4
- Waller et al. J Urol 1995;153.345-8
- Li et al. Arch Phys Med Rehabil. 2013;94:782-7
- Hakansson et al. Urol Nurs. 2015;35:239-47
- Rognoni and Tarricone. Health Technology Assessment (HTA), CERGAS Bocconi University 2016